Semaglutide

In the STEP 1 clinical trial published in the New England Journal of Medicine in 2021, participants taking 2.4 mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks. About one-third of participants achieved 20% or greater weight loss. For a 250-pound person, this translates to roughly 37 pounds on average, with some losing 50+ pounds. Results vary based on starting weight, diet, exercise, and individual response.

The most common side effects are gastrointestinal. In the STEP 1 trial, 44% experienced nausea, 30% diarrhea, 24% vomiting, and 24% constipation. These typically occur during the dose escalation period (first 16-20 weeks) and improve significantly once you reach your maintenance dose. Starting low (0.25 mg) and titrating slowly is the key to managing GI side effects.

Yes. Semaglutide is FDA-approved for chronic weight management under the brand name Wegovy at 2.4 mg weekly injection for adults with BMI 30+ (or BMI 27+ with a weight-related comorbidity). It was also approved for adolescents aged 12+ in 2022. In December 2025, the FDA approved an oral formulation of Wegovy (25 mg tablet), making it the first oral GLP-1 for weight management.

Yes, the research clearly shows weight regain after discontinuation. The STEP 4 trial found participants regained approximately two-thirds of lost weight within one year of stopping semaglutide. The STEP 5 two-year trial confirmed that continued treatment maintains weight loss while stopping leads to regain. This is why most physicians recommend ongoing treatment, similar to managing blood pressure or cholesterol.

All three contain semaglutide but differ in formulation and FDA approval. Ozempic is the injectable form approved for type 2 diabetes (max 2.0 mg/week). Wegovy is the injectable form approved for weight management (2.4 mg/week). Rybelsus is the oral tablet approved for diabetes. They contain the same active ingredient at different doses and have different FDA-approved indications.

Studies show that 25-40% of weight lost on semaglutide is lean mass (including muscle) rather than fat. This is similar to other forms of weight loss. The STEP 1 trial showed average lean mass loss of about 8 lbs alongside 27 lbs of fat loss. Resistance training and adequate protein intake (1.0-1.2 g/kg body weight) during treatment can help preserve muscle mass.

Most people notice reduced appetite within the first 1-2 weeks of starting semaglutide. Measurable weight loss typically begins by week 4-8. However, the full dose titration takes 16-20 weeks, so maximum weight loss effects are not achieved until you have been on the full 2.4 mg dose for several weeks. The STEP trials show weight loss continues through 68 weeks before plateauing.

The SELECT trial — the largest cardiovascular outcomes trial for an anti-obesity medication (17,604 participants) — showed semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo. This led to an expanded FDA label for cardiovascular risk reduction. Semaglutide also modestly increases heart rate by 1-4 bpm on average.

There is no direct interaction between semaglutide and alcohol. However, because semaglutide slows gastric emptying, alcohol may be absorbed differently and its effects may feel stronger. Many users report lower alcohol tolerance. Additionally, alcohol adds empty calories that can undermine weight loss goals. Most physicians recommend moderating alcohol intake while on semaglutide.

The list price for Wegovy (weight loss indication) is approximately $1,300/month without insurance. Ozempic (diabetes indication) costs approximately $935/month. Insurance coverage varies significantly — some plans cover Wegovy for obesity, others do not. Manufacturer savings programs, GoodRx coupons, and compounding pharmacies may reduce costs. Generic semaglutide is not expected until 2031+ due to patent protection.

If you miss your weekly injection, take it as soon as you remember within 5 days of the missed dose. If more than 5 days have passed, skip the missed dose and take your next dose on the regularly scheduled day. Do not take a double dose. Semaglutide has a 7-day half-life, so a single missed dose should not cause significant weight regain, but try to maintain a consistent weekly schedule.

The term "Ozempic face" refers to facial volume loss that can occur with significant weight loss from any cause. As body fat decreases, facial fat pads shrink, which can make the face appear more gaunt or aged. This is not unique to semaglutide — it happens with any substantial weight loss. Slower weight loss, adequate protein intake, and dermal fillers (cosmetic choice) are potential mitigations.